{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'In addition, hospitalizations for planned procedures are not considered an AE unless they are', 'prolonged hospitalizations, and emergency room visits less than 24 hours in duration are not', 'considered hospitalizations.', '9.5.4.1.1.3 Non-Serious Adverse Event Definition', 'A non-serious AE includes any AE that is not described in the previous SAE category.', '9.5.4.1.1.4 Unexpected Adverse Event Definition', 'An AE or suspected adverse reaction is considered unexpected if it is not listed in the Reference', 'Safety Information section of the IB or is not listed with the specificity or severity that has been', 'observed. Unexpected, as used in this definition, also refers to AEs or suspected adverse', 'reactions that are mentioned in the Reference Safety Information as occurring with a class of', 'drugs or as anticipated from the pharmacological properties of the drug, but are not specifically', 'mentioned as occurring with the particular drug under investigation.', '9.5.4.1.1.5 Adverse Events of Special Interest', 'Based on previous clinical experience in TED, the following AESIs are identified for this study', '(See Section 7.1.3.4.5.5 for further information):', 'Infusion reactions (e.g., nausea, vomiting, facial flushing, warmth, dyspnea, dizziness,', 'hypertension, hypotension, pruritus)', 'Hyperglycemia', 'Muscle spasms', 'Diarrhea', '9.5.4.1.2 Documentation of Adverse Events', 'Adverse events that are ongoing at the completion of HZNP-TEP-301 and/or occur prior to', 'dosing on Day 1 will be considered pre-dose AEs. The TEAE reporting period begins with', 'administration of the first dose of study medication on Day 1 and continues until 3 weeks after', 'the last dose of study drug, and the Follow-Up AE reporting period begins 3 weeks after the last', 'dose of study drug through completion of the Follow-Up Period (Month 12 or PW). All pre-dose', 'AEs, TEAEs, and AEs during the Follow-Up Period must be recorded in the source documents', \"and in the subject's eCRF.\", 'If the Investigator observes an SAE after study completion that he/she believes was possibly', 'caused by the study medication, the Investigator will report this SAE using the procedures', 'described in Section 9.5.4.1.5.', 'Detailed information regarding all SAEs must also be recorded on the Serious Adverse Event', 'Reporting Form. Whenever possible, the Investigator should group together into a single term', 'the signs and symptoms that constitute a single diagnosis. For example, cough, rhinitis, and', 'sneezing might be grouped together as \"upper respiratory infection\" if the Investigator is', 'confident of the diagnosis.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 87 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.5.4.1.3 Intensity of Adverse Events', 'All clinical AEs encountered during the clinical study will be reported on the AE form of the', 'CRF. Intensity of AEs will be graded on a 5-point scale (mild, moderate, severe, life-threatening,', 'death) and reported in detail on the eCRF.', 'Intensity', 'Definition', 'Corresponding NCI Grade', 'Mild', 'discomfort noticed but no disruption of normal daily activity', '1', 'Moderate', 'discomfort sufficient to reduce or affect daily activity', '2', 'Severe', 'inability to work or perform normal daily activity', '3', 'Life-Threatening', 'represents an immediate threat to life', '4', 'Fatal', 'results in death', '5', '9.5.4.1.4 Relationship to Study Drug', 'The relationship of the study drug to each AE will be determined by the Investigator and the', 'Sponsor based on the following definitions:', 'No reasonable causal relationship (probably not related): There is no plausible temporal', 'relationship or there is another explanation that unequivocally provides a more plausible', 'explanation for the event.', 'Yes, reasonable causal relationship (possibly related): There is evidence in favor of a', 'causal relationship (i.e., there is a plausible time course) and at least one of the following', 'criteria apply:', 'There is a reasonable pharmacological relationship (or known class effect)', 'There is no other more plausible explanation', 'There is a positive de-challenge (without active treatment of the event)', 'There is a positive re-challenge', 'There is a distinguishable dose effect', 'Within the reporting requirement under 21 CFR 312.32(c)(1)(i), the FDA provides the following', 'examples of types of evidence that would suggest a causal relationship between the drug and the', 'AE.', 'A single occurrence of an event that is uncommon and known to be strongly associated', 'with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 88 of 118']\n\n###\n\n", "completion": "END"}